• Citer

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.

par Eggermont, A;Suciu, Stefan ;Mackie, Rona;Ruka, Wlodzimierz;Testori, Alessandro;Kruit, Wim H;Punt, Cornelis;Delauney, Michelle;Sales, François ;Groenewegen, Gerard;Ruiter, D J;Jagiello, Izabella;Stoitchkov, K;Keilholz, Ulrich;Lienard, Danielle ;EORTC Melanoma Group,
Référence Lancet, 366, 9492, page (1189-1196)
Publication Publié, 2005-10

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
Auteur:	Eggermont, A; Suciu, Stefan; Mackie, Rona; Ruka, Wlodzimierz; Testori, Alessandro; Kruit, Wim H; Punt, Cornelis; Delauney, Michelle; Sales, François; Groenewegen, Gerard; Ruiter, D J; Jagiello, Izabella; Stoitchkov, K; Keilholz, Ulrich; Lienard, Danielle; EORTC Melanoma Group,
Informations sur la publication:	Lancet, 366, 9492, page (1189-1196)
Statut de publication:	Publié, 2005-10
Sujet CREF:	Cancérologie
MeSH keywords:	Adult
	Aged
	Antineoplastic Agents -- adverse effects -- therapeutic use
	Chemotherapy, Adjuvant
	Combined Modality Therapy
	Female
	Humans
	Interferon-alpha -- adverse effects -- therapeutic use
	Lymphatic Metastasis
	Male
	Melanoma -- drug therapy -- pathology -- secondary -- surgery
	Middle Aged
	Recombinant Proteins
	Skin Neoplasms -- drug therapy -- pathology -- surgery
Note générale:	Clinical Trial
	Journal Article
	Multicenter Study
	Randomized Controlled Trial
	Research Support, N.I.H., Extramural
	Research Support, Non-U.S. Gov't
	Research Support, U.S. Gov't, P.H.S.
	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0140-6736
	info:doi/10.1016/S0140-6736(05)67482-X
	info:pii/S0140-6736(05)67482-X
	info:scp/25844465690
	info:pmid/16198768